Market Overview

UPDATE: Morgan Stanley Downgrades Mylan to Equal-Weight Following Outperformance

Related MYL
Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Lowest PEG Ratio
Mylan Launches First Generic Version Of Orapred ODT
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)

Morgan Stanley downgraded Mylan Inc. (NASDAQ: MYL) from Overweight to Equal-weight and removed the price target of $27.00.

Morgan Stanley commented, "Mylan is above our previous $27 price target, and we are downgrading from OW to EW on a more balanced risk-reward. The market now appears to be pricing in better growth prospects in EMEA and the potential for accretive M&A."

Mylan closed at $27.91 on Monday.

Latest Ratings for MYL

DateFirmActionFromTo
Sep 2014ISI GroupInitiates Coverage on
Aug 2014RBC CapitalDowngradesOutperformSector Perform
Aug 2014CitigroupMaintainsNeutral

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (MYL)

Around the Web, We're Loving...

Get Benzinga's Newsletters